title: A mitogen-activated protein kinase kinase inhibitor induced compound skin toxicity with oedema in metastatic malignant melanoma.
abstract: We report three cases of skin toxicity associated with oral mitogen-activated protein kinase kinase (MEK) inhibitor treatment for metastatic malignant melanoma (MM). All three patients developed oedema, and a single patient experienced eyelash trichomegaly. This is the first known report of eyelash trichomegaly secondary to MEK inhibitor use. We also discuss possible mechanisms for MEK inhibitor-associated oedema development. This series supports the role of the dermatologist in the screening and management of patients in the rapidly developing oncology setting, as new targeted agents can give rise to marked skin toxicity.
authors.affiliation: Department of Dermatology, St George's Hospital, London, UK.
authors.forename: C L
authors.initials: CL
authors.lastname: Thomas
authors.affiliation: Department of Dermatology, St George's Hospital, London, UK.|Department of Dermatology, The Royal Marsden Hospital, London, UK.
authors.forename: P S
authors.initials: PS
authors.lastname: Mortimer
authors.affiliation: Department of Oncology, The Royal Marsden Hospital, London, UK.
authors.forename: J M
authors.initials: JM
authors.lastname: Larkin
authors.affiliation: Department of Dermatology, King's College Hospital, London, UK.
authors.forename: T N
authors.initials: TN
authors.lastname: Basu
authors.affiliation: Department of Oncology, The Royal Marsden Hospital, London, UK.
authors.forename: M E
authors.initials: ME
authors.lastname: Gore
authors.affiliation: Department of Dermatology, The Royal Marsden Hospital, London, UK.
authors.forename: L
authors.initials: L
authors.lastname: Fearfield
mesh_terms: D000181:Acrylonitrile / Q000009:adverse effects / Q000031:analogs & derivatives*; D000328:Adult; D000814:Aniline Compounds / Q000009:adverse effects*; D004487:Edema / Q000139:chemically induced*; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D012871:Skin Diseases / Q000139:chemically induced*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000556:secondary
chemical_list: D000814:Aniline Compounds; C000610759:MEK inhibitor I; D047428:Protein Kinase Inhibitors; D020929:Mitogen-Activated Protein Kinase Kinases; D000181:Acrylonitrile